

THE COST ANALYSIS OF ANTIDIABETIC ON OUTPATIENTS OF DIABETES MELLITUS TYPE 2 WITH OBESITY USING NATIONAL HEALTH INSURANCE(JKN) IN BANTUL HOSPITAL

Septya Eky Drabinarse
Department of Pharmacy

ABSTRACT

Overweight and obesity are the biggest risk factors for patients with diabetes mellitus who need long therapy and with high costs. Therefore, the government held a National Health Insurance (JKN) program with the INA CBG's payment system to facilitate objective calculation of tariffs. This study aims to determine the description of therapy, clinical outcomes, the magnitude of direct medical costs based on the hospital perspective and the difference in real costs with INA CBG's rates in obesity outpatients of diabetes mellitus type 2. The research was an analytic observational study using a cross sectional design and sampling using a purposive sampling method. The subjects of the study were outpatient of diabetes mellitus type 2 with obesity participating in the National Health Insurance (JKN) in Bantul Hospital with 89 patients being used as subjects. The analysis aims to see the difference in INA CBG's rates and claim costs using the One Sample T-Test statistical test and Man Whitney test. The results showed that the most therapy in outpatients of DM type 2 with obesity was a combination of insulin novomix and metformin, clinical outcomes in patients with a body mass index of $\geq 25 \text{ kg/m}^2$ - 29.9 kg/m^2) and $\geq 30 \text{ kg/m}^2$ - 40 kg/m^2) each of 42,46% and 51,36%, the total direct medical cost was Rp. 531.034 from 89 patients based on the hospital perspective. The comparison between the average real cost of 7 days and the INA CBG's tariff is Rp. 183,300 using the One Sample T-test with a value of $p = 0,000$ or $p < 0,05$ which indicates that there is a significant difference between 7 days real costs and INA CBG's rates, and claim costs 23 days with the Man Whitney test obtained $p \text{ value} = 0.945$ or $p > 0.05$ which indicates there is no significant difference between the real cost of 23 days compared to the cost of claims for chronic disease drugs.

Keyword : Diabetes Melitus Type 2, JKN, Obesity